Physician profile
Amanda Massaro Strileckis
NPI 1578294633
$8,953.21
in general payments reported to CMS, 2019-2025
28 companies · $1,787 in 2025
The $1,787 reported for 2025 was more than what 93% of Gerontology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $161).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $976 · 2023: $3,212 · 2024: $2,978 · 2025: $1,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,578 · Education: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,578.21 |
| Education | $398.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,231.13 | 2022-2025 | |
| Janssen Biotech, INC. | $1,081.26 | 2022-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $1,028.02 | 2022-2025 | Enbrel, Otezla, Krystexxa |
| Mallinckrodt Hospital Products INC. | $895.08 | 2022-2025 | Acthar |
| Horizon Therapeutics Plc | $597.77 | 2022-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $472.18 | 2022-2025 | Saphnelo |
| Lilly USA, LLC | $386.20 | 2022-2024 | Taltz, Zepbound |
| Ucb, INC. | $295.23 | 2022-2024 | Cimzia, Bimzelx |
| Genzyme Corporation | $274.21 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $228.50 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.14 | 2023-2025 | Ofev, Cyltezo |
| Ani Pharmaceuticals, INC. | $162.81 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $149.52 | 2022-2025 | Benlysta |
| Sobi, INC | $144.21 | 2022-2025 | |
| Si-Bone, INC. | $141.72 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $113.87 | 2023-2025 | Monovisc, Orthovisc |
| Almatica Pharma LLC | $101.36 | 2022-2025 | Teriparatide, Gralise |
| Organon LLC | $78.91 | 2023-2025 | Hadlima, Renflexis |
| Radius Health, INC. | $68.39 | 2022-2023 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $66.26 | 2024-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $46.96 | 2024 | Lupkynis |
| Azurity Pharmaceuticals, INC. | $46.16 | 2023-2024 | Horizant, Horizant |
| Fresenius Kabi USA, LLC | $42.05 | 2024 | Idacio |
| Sandoz INC. | $38.96 | 2024-2025 | Hyrimoz, Jubbonti |
| Pfizer INC. | $37.53 | 2023-2024 | |
| Grifols USA, LLC | $23.33 | 2024 | Gamunex-C |
| Biogen, INC. | $20.42 | 2023 | Tysabri |
| Bioventus LLC | $16.03 | 2023 | Durolane |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Strileckis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.